Search Results

Seliciclib 10 mg  | 100.00%

TargetMol

Seliciclib (Roscovitine) is a potent inhibitor of Cdk2/cyclin E (IC50: 0.1 μM). It also inhibits Cdk7/cyclin H, Cdk5/p35, and Cdc2/cyclin B (IC50s: 0.49/0.16/0.65 μM).

More Information Supplier Page

Xanthohumol 100 mg  | 99.18%

TargetMol

Xanthohumol, also known as 2′, 4, 4′-trihydroxy-6′-methoxy-3′-prenylchalcone or desmethylxanthohumol, is a member of the class of compounds known as 3-prenylated chalcones. It inhibits COX-1 and COX-2 activity and shows chemopreventive effects.

More Information Supplier Page

Xanthohumol 50 mg  | 99.18%

TargetMol

Xanthohumol, also known as 2′, 4, 4′-trihydroxy-6′-methoxy-3′-prenylchalcone or desmethylxanthohumol, is a member of the class of compounds known as 3-prenylated chalcones. It inhibits COX-1 and COX-2 activity and shows chemopreventive effects.

More Information Supplier Page

Xanthohumol 5 mg  | 99.18%

TargetMol

Xanthohumol, also known as 2′, 4, 4′-trihydroxy-6′-methoxy-3′-prenylchalcone or desmethylxanthohumol, is a member of the class of compounds known as 3-prenylated chalcones. It inhibits COX-1 and COX-2 activity and shows chemopreventive effects.

More Information Supplier Page

Xanthohumol 25 mg  | 99.18%

TargetMol

Xanthohumol, also known as 2′, 4, 4′-trihydroxy-6′-methoxy-3′-prenylchalcone or desmethylxanthohumol, is a member of the class of compounds known as 3-prenylated chalcones. It inhibits COX-1 and COX-2 activity and shows chemopreventive effects.

More Information Supplier Page

Seliciclib 25 mg  | 100.00%

TargetMol

Seliciclib (Roscovitine) is a potent inhibitor of Cdk2/cyclin E (IC50: 0.1 μM). It also inhibits Cdk7/cyclin H, Cdk5/p35, and Cdc2/cyclin B (IC50s: 0.49/0.16/0.65 μM).

More Information Supplier Page

Seliciclib 50 mg  | 100.00%

TargetMol

Seliciclib (Roscovitine) is a potent inhibitor of Cdk2/cyclin E (IC50: 0.1 μM). It also inhibits Cdk7/cyclin H, Cdk5/p35, and Cdc2/cyclin B (IC50s: 0.49/0.16/0.65 μM).

More Information Supplier Page

Amuvatinib 5 mg  | Purity Not Available

TargetMol

Amuvatinib is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.

More Information Supplier Page